Geron Corporation Halts Stem Cell Trial

Geron Corporation is leaving the field that it helped pioneer. It was a calculated business move to sink so much money into embryonic stem cell-derived stem cells. This illustrates the long, expensive path it takes to make stem cell-based products. Late Monday, the company said it would halt its study of a stem cell-based treatment for spinal cord injury, which is the first embryonic stem cell trial approved in the U.S. Now Geron is putting its stem cell division up for sale.

See the rest of the story here.

Published by


Professor of Biochemistry at Spring Arbor University (SAU) in Spring Arbor, MI. Have been at SAU since 1999. Author of The Stem Cell Epistles. Before that I was a postdoctoral research fellow at the University of Pennsylvania in Philadelphia, PA (1997-1999), and Sussex University, Falmer, UK (1994-1997). I studied Cell and Developmental Biology at UC Irvine (PhD 1994), and Microbiology at UC Davis (MA 1986, BS 1984).